Document is current
Any future updates will be listed below
-
Authors
Zovich, Beatrice
Freeland, Catherine
Moore, Holly
Sapp, Kara
Qureshi, Anousha
Jessop, Amy
Holbert, Rachel
Borondy-Jenkins, Fiona
Plunkett, Quinn
Cohen, Chari
-
Funding
Funding for this research was provided by:
Gilead Sciences (IN-US-980-6671, IN-US-980-6671, IN-US-980-6671, IN-US-980-6671, IN-US-980-6671, IN-US-980-6671, IN-US-980-6671, IN-US-980-6671, IN-US-980-6671, IN-US-980-6671)
- License Information
-
More Information
Article History
Received: 10 May 2024
Accepted: 1 November 2024
First Online: 15 November 2024
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of the City of Philadelphia Department of Public Health (Project Number: 2023-33) on August 7th, 2023, and Heartland IRB (Project Number: 02202023-457) on February 20th, 2023.
: Not applicable.
: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The Hepatitis B Foundation receives program and research grants from Gilead Sciences, VBI Vaccines, GSK, and Genentech. Beatrice Zovich has received compensation for serving on an advisory committee for Gilead Sciences, Inc. Chari Cohen sits on a patient advocacy advisory committee for GSK (with funds going to the Foundation).
